学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

神垣隆（カミガキタカシ）

研究テーマ	再生医療、特に免疫細胞療法の開発
研究業績（論文）	I．英文原著 1. Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma. <https://pubmed.ncbi.nlm.nih.gov/37676069/> Kida A, Mizukoshi E, Kitahara M, Miyashita T, Goto S, Kamigaki T, Takimoto R, Asai J, Kakinoki K, Urabe T, Tomita K, Kaneko S. Int J Cancer. 2023 Sep 7. doi: 10.1002/ijc.34716. Online ahead of print. PMID: 37676069 2. Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG). <https://pubmed.ncbi.nlm.nih.gov/37486281/> Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, Yasuda H, Ohgino K, Terai H, Tomita K, Miura M, Mizukoshi E, Miyashita T, Nakamoto Y, Hayashi K, Miwa S, Kitahara M, Takeuchi A, Kimura H, Mochizuki T, Sugie H, Seino KI, Yamada T, Takeuchi S, Makita K, Naitoh K, Yasumoto K, Yoshida Y, Inoue H, Kotake K, Ohshima K, Noda SE, Okamoto M, Yoshimoto Y, Okada S, Ibe H, Oguma E, Goto S; CITEG. Cytotherapy. 2023 Jul 22:S1465-3249(23)00984-2. doi: 10.1016/j.jcyt.2023.06.007. Online ahead of print. PMID: 37486281 3. Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors. <https://pubmed.ncbi.nlm.nih.gov/35896218/> Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Goto S. Anticancer Res. 2022 Aug;42(8):4179-4187. doi:10.21873/anticanres.15918. PMID: 35896218 4. Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy. <https://pubmed.ncbi.nlm.nih.gov/34281884/> Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Goto S. Anticancer Res. 2021 Aug;41(8):4133-4141. doi: 10.21873/anticanres.15216. PMID: 34281884 5. Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports. <https://pubmed.ncbi.nlm.nih.gov/33827668/> Takimoto R, Kamigaki T, Gotoda T, Takahashi T, Okada S, Ibe H, Oguma E, Goto S. J Med Case Rep. 2021 Apr 8;15(1):191. doi: 10.1186/s13256-020-02634-z. PMID: 33827668 Free PMC article. 6. Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. <https://pubmed.ncbi.nlm.nih.gov/32907781/> Kumai T, Mizukoshi E, Hashiba T, Nakagawa H, Kitahara M, Miyashita T, Mochizuki T, Goto S, Kamigaki T, Takimoto R, Yamashita T, Sakai Y, Yamashita T, Honda M, Tomita K, Kaneko S. Cytotherapy. 2021 Feb;23(2):137-145. doi: 10.1016/j.jcyt.2020.08.001. Epub 2020 Sep 6. PMID: 32907781 7.Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy. Yamada T, Yoshida Y, Maeda T, Yoshimatsu G, Aisu N, Yamashita K, Komono A, Kajitani R, Matsumoto Y, Nagano H, Naito K, Yasumoto K, Takimoto R, Kamigaki T, Goto S, Yoshimura F, Sakata N, Kodama S, Hasegawa S. Anticancer Res. 2020 Aug;40(8):4763-4771. doi: 10.21873/anticanres.14478. PMID: 32727803 8.Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix. Goto S, Terao Y, Kamigaki T, Takimoto R, Naitoh K, Makita K, Yasumoto K, Okada S, Takizawa K, Yokomichi N, Suzuki N, Takeda S. Anticancer Res. 2020 Aug;40(8):4741-4748. doi: 10.21873/anticanres.14475. PMID: 32727800 9.Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study. Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, Makita K, Yasumoto K, Goto S. Anticancer Res. 2020 Aug;40(8):4729-4740. doi: 10.21873/anticanres.14474. PMID: 32727799 10.Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. Miura M, Mizukoshi E, Hashiba T, Kitahara M, Miyashita T, Mochizuki T, Goto S, Kamigaki T, Takimoto R, Yamashita T, Sakai Y, Yamashita T, Honda M, Kaneko S. Cancer Med. 2020 Jul;9(14):4907-4917. doi: 10.1002/cam4.3152. Epub 2020 Jun 11. PMID: 32529780 Free PMC article. 11.Identification of prognostic factors for γδT cell immunotherapy in patients with solid tumor. Takimoto R, Miyashita T, Mizukoshi E, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, Yasumoto K, Makita K, Tomita K, Goto S. Cytotherapy. 2020 Jun;22(6):329-336. doi: 10.1016/j.jcyt.2020.02.008. Epub 2020 Apr 14. PMID: 32303429 12.Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study. Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S. Anticancer Res. 2019 Aug;39(8):4525-4532. doi: 10.21873/anticanres.13629. PMID: 31366555 13.Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy. Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S. Anticancer Res. 2018 Jul;38(7):4353-4360. doi: 10.21873/anticanres.12736. PMID: 29970573 14.Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial. Hirooka Y, Kawashima H, Ohno E, Ishikawa T, Kamigaki T, Goto S, Takahara M, Goto H. Oncotarget. 2017 Dec 5;9(2):2838-2847. doi:10. 18632/oncotarget.22974. eCollection 2018 Jan 5. PMID: 29416816 Free PMC article. 15. Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B. Miyashita T, Miki K, Kamigaki T, Makino I, Tajima H, Nakanuma S, Hayashi H, Takamura H, Fushida S, Ahmed AK, Harmon JW, Ohta T. Oncol Lett. 2017 Nov;14(5):5918-5926. doi:10.3892/ol. 2017.6943. Epub 2017 Sep 14. PMID: 29113227 Free PMC article. 16.Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study. Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S. Anticancer Res. 2017 Jul;37(7):3947-3954. doi: 10.21873/anticanres.11778. PMID: 28668899 17.Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study). Yoshida Y, Naito M, Yamada T, Aisu N, Kojima D, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Gotoh S, Kodama S, Yamashita Y, Hasegawa S. Anticancer Res. 2017 Jul;37(7):3941-3946. doi: 10.21873/anticanres.11777. PMID: 28668898 Clinical Trial. 18.Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells. Ishii F, Yoshida Y, Yamauchi Y, Aisu N, Kojima D, Mera T, Kato D, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Hamada Y, Nimura S, Kodama S, Hasegawa S. Anticancer Res. 2017 Jul;37(7):3933-3939. doi: 10.21873/anticanres.11776. PMID: 28668897 19.Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma. Kanemura Y, Sumida M, Okita Y, Yoshioka E, Yamamoto A, Kanematsu D, Handa Y, Fukusumi H, Inazawa Y, Takada AI, Nonaka M, Nakajima S, Mori K, Goto S, Kamigaki T, Shofuda T, Moriuchi S, Yamasaki M. Anticancer Res. 2017 Jul;37(7):3921-3932. doi: 10.21873/anticanres.11775. PMID: 28668896 20.Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, Okada N. Mol Ther Oncolytics. 2016 Nov 16;3:16024. doi: 10.1038/mto. 2016.24. eCollection 2016. PMID: 27909701 Free PMC article. 21.Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer. Yoshida Y, Naito M, Yamada T, Aisu N, Daibo K, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Yamashita Y, Hasegawa S. Anticancer Res. 2016 Jul;36(7):3741-6. PMID: 27354648 22.Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells. Naitoh K, Kamigaki T, Matsuda E, Ibe H, Okada S, Oguma E, Kinoshita Y, Takimoto R, Makita K, Ogasawara S, Goto S. Anticancer Res. 2016 Jul;36(7):3715-24. PMID: 27354645 23.Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer. Yamashita K, Hasegawa H, Fujita M, Nishi M, Tanaka T, Arimoto A, Suzuki S, Kamigaki T, Kakeji Y. Anticancer Res. 2016 Jul;36(7):3659-65. PMID: 27354637 24.Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer. Miyashita T, Miki K, Kamigaki T, Makino I, Nakagawara H, Tajima H, Takamura H, Kitagawa H, Fushida S, Ahmed AK, Duncan MD, Harmon JW, Ohta T. Clin Exp Med. 2017 Feb;17(1):19-31. doi: 10.1007/s10238-015-0394-x. Epub 2015 Oct 8. PMID: 26449615 Ⅱ和文原著 Ⅲ　英文総説 1.Zoledronate-pulsed dendritic cell-based anticancer vaccines: Kamigaki T, Takahara M, Maekawa R, Goto S. Oncoimmunology 2: e25636, 2013, IF: Ⅳ　和文総説 1. がん免疫療法の分類と作用機序　免疫細胞療法とは何か後藤重則, 神垣隆, 瀧澤憲臨床婦人科産科 72巻6号 Page550-556(2018.06) DOI：10.11477/mf.1409209418 2. 【悪性腫瘍と免疫療法-呼吸器悪性腫瘍を中心に-】免疫細胞療法の現状と展望後藤重則, 瀧本理修, 牧田香理, 内藤恵子, 神垣隆呼吸器内科 31巻4号 Page323-330(2017.04) 3. 【Precision Medicine時代の治療と診断】免疫細胞療法の現状と今後の展開神垣隆, 阿曽沼元博, 後藤重則映像情報Medical(1346-1354)49巻4号 Page28-33(2017.04) 4. がん免疫細胞療法　腫瘍ライセートを用いた固形腫瘍に対する樹状細胞ワクチン療法神垣隆, 高原将司, 照屋剛, 城間寛, 善本隆之, 後藤重則日本臨床 75巻2号 Page288-294(2017.02) 5.がん免疫治療神垣隆, 内藤恵子, 牧田香理, 瀧本理修, 後藤重則 Source：腎臓内科・泌尿器科 3巻3号 Page294-302(2016.03) 6. 免疫細胞療法と肺がん後藤重則), 内藤恵子, 神垣隆呼吸器内科 28巻6号 Page463-468(2015.12) Ⅴ　英文著書 Ⅵ　和文著書 1.T細胞輸注療法　～肺癌・膵癌を中心として～神垣隆, 後藤重則第8章　第3節、2016年 Ⅶ　英文報告その他 1.Saito M, Yano K, Kamigaki T, Goto S. A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). Anticancer Res 33: 2957-63, 2013, IF: Ⅷ　和文報告その他（科学研究費補助金・各種助成金等） 1.末梢血PD-1陽性腫瘍特異的Tリンパ球を用いた複合がん免疫療法の開発研究種目　基盤研究(C)　研究機関　順天堂大学研究代表者　神垣　隆順天堂大学, 医学(系)研究科(研究院) 研究期間　　2019-04-01 – 2022-03-31 2.同種異系反応に伴う免疫活性化機構の解明と新規標的分子の同定（分担）研究種目　基盤研究(C)　研究機関　神戸大学研究代表者　山下公大神戸大学, 医学部附属病院研究期間　　2016-04-01 – 2019-03-31 3.進行食道癌におけるペプチドプールを用いた術後補助免疫療法の確立（分担）研究種目　基盤研究(C)　研究機関　神戸大学研究代表者　中村哲神戸大学, 医学部附属病院研究期間　　2015-04-01 – 2018-03-31 4.NKT細胞の自然免疫と獲得免疫のクロストークを用いた癌治療法の開発（分担）研究種目　基盤研究(C)　研究機関　神戸大学研究代表者　山下公大神戸大学, 医学部附属病院研究期間　　2013-04-01 – 2016-03-31

研究テーマ

再生医療、特に免疫細胞療法の開発

研究業績（論文）

I．英文原著

1. Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma. <https://pubmed.ncbi.nlm.nih.gov/37676069/>
Kida A, Mizukoshi E, Kitahara M, Miyashita T, Goto S, Kamigaki T, Takimoto R, Asai J, Kakinoki K, Urabe T, Tomita K, Kaneko S.
Int J Cancer. 2023 Sep 7. doi: 10.1002/ijc.34716. Online ahead of print.
PMID: 37676069

2. Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG). <https://pubmed.ncbi.nlm.nih.gov/37486281/>
Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, Yasuda H, Ohgino K, Terai H, Tomita K, Miura M, Mizukoshi E, Miyashita T, Nakamoto Y, Hayashi K, Miwa S, Kitahara M, Takeuchi A, Kimura H, Mochizuki T, Sugie H, Seino KI, Yamada T, Takeuchi S, Makita K, Naitoh K, Yasumoto K, Yoshida Y, Inoue H, Kotake K, Ohshima K, Noda SE, Okamoto M, Yoshimoto Y, Okada S, Ibe H, Oguma E, Goto S; CITEG.
Cytotherapy. 2023 Jul 22:S1465-3249(23)00984-2. doi: 10.1016/j.jcyt.2023.06.007. Online ahead of print.
PMID: 37486281

3. Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors. <https://pubmed.ncbi.nlm.nih.gov/35896218/>
Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Goto S.
Anticancer Res. 2022 Aug;42(8):4179-4187. doi:10.21873/anticanres.15918.
PMID: 35896218

4. Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy. <https://pubmed.ncbi.nlm.nih.gov/34281884/>
Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Goto S.
Anticancer Res. 2021 Aug;41(8):4133-4141. doi: 10.21873/anticanres.15216.
PMID: 34281884

5. Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports. <https://pubmed.ncbi.nlm.nih.gov/33827668/>
Takimoto R, Kamigaki T, Gotoda T, Takahashi T, Okada S, Ibe H, Oguma E, Goto S.
J Med Case Rep. 2021 Apr 8;15(1):191. doi: 10.1186/s13256-020-02634-z.
PMID: 33827668 Free PMC article.

6. Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. <https://pubmed.ncbi.nlm.nih.gov/32907781/>
Kumai T, Mizukoshi E, Hashiba T, Nakagawa H, Kitahara M, Miyashita T, Mochizuki T, Goto S, Kamigaki T, Takimoto R, Yamashita T, Sakai Y, Yamashita T, Honda M, Tomita K, Kaneko S. Cytotherapy. 2021 Feb;23(2):137-145. doi: 10.1016/j.jcyt.2020.08.001. Epub 2020 Sep 6.
PMID: 32907781

7.Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy.
Yamada T, Yoshida Y, Maeda T, Yoshimatsu G, Aisu N, Yamashita K, Komono A, Kajitani R, Matsumoto Y, Nagano H, Naito K, Yasumoto K, Takimoto R, Kamigaki T, Goto S, Yoshimura F, Sakata N, Kodama S, Hasegawa S.
Anticancer Res. 2020 Aug;40(8):4763-4771. doi: 10.21873/anticanres.14478. PMID: 32727803

8.Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix.
Goto S, Terao Y, Kamigaki T, Takimoto R, Naitoh K, Makita K, Yasumoto K, Okada S, Takizawa K, Yokomichi N, Suzuki N, Takeda S.
Anticancer Res. 2020 Aug;40(8):4741-4748. doi: 10.21873/anticanres.14475. PMID: 32727800

9.Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study.
Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, Makita K, Yasumoto K, Goto S.
Anticancer Res. 2020 Aug;40(8):4729-4740. doi: 10.21873/anticanres.14474. PMID: 32727799

10.Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer.
Miura M, Mizukoshi E, Hashiba T, Kitahara M, Miyashita T, Mochizuki T, Goto S, Kamigaki T, Takimoto R, Yamashita T, Sakai Y, Yamashita T, Honda M, Kaneko S.
Cancer Med. 2020 Jul;9(14):4907-4917. doi: 10.1002/cam4.3152. Epub 2020 Jun 11. PMID: 32529780 Free PMC article.

11.Identification of prognostic factors for γδT cell immunotherapy in patients with solid tumor.
Takimoto R, Miyashita T, Mizukoshi E, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, Yasumoto K, Makita K, Tomita K, Goto S.
Cytotherapy. 2020 Jun;22(6):329-336. doi: 10.1016/j.jcyt.2020.02.008. Epub 2020 Apr 14. PMID: 32303429

12.Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study.
Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S.
Anticancer Res. 2019 Aug;39(8):4525-4532. doi: 10.21873/anticanres.13629. PMID: 31366555

13.Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S.
Anticancer Res. 2018 Jul;38(7):4353-4360. doi: 10.21873/anticanres.12736. PMID: 29970573

14.Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial.
Hirooka Y, Kawashima H, Ohno E, Ishikawa T, Kamigaki T, Goto S, Takahara M, Goto H.
Oncotarget. 2017 Dec 5;9(2):2838-2847. doi:10. 18632/oncotarget.22974. eCollection 2018 Jan 5.
PMID: 29416816 Free PMC article.

15. Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B.
Miyashita T, Miki K, Kamigaki T, Makino I, Tajima H, Nakanuma S, Hayashi H, Takamura H, Fushida S, Ahmed AK, Harmon JW, Ohta T.
Oncol Lett. 2017 Nov;14(5):5918-5926. doi:10.3892/ol. 2017.6943. Epub 2017 Sep 14. PMID: 29113227 Free PMC article.

16.Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study.
Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S.
Anticancer Res. 2017 Jul;37(7):3947-3954. doi: 10.21873/anticanres.11778. PMID: 28668899

17.Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study).
Yoshida Y, Naito M, Yamada T, Aisu N, Kojima D, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Gotoh S, Kodama S, Yamashita Y, Hasegawa S.
Anticancer Res. 2017 Jul;37(7):3941-3946. doi: 10.21873/anticanres.11777. PMID: 28668898 Clinical Trial.

18.Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.
Ishii F, Yoshida Y, Yamauchi Y, Aisu N, Kojima D, Mera T, Kato D, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Hamada Y, Nimura S, Kodama S, Hasegawa S.
Anticancer Res. 2017 Jul;37(7):3933-3939. doi: 10.21873/anticanres.11776. PMID: 28668897

19.Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Kanemura Y, Sumida M, Okita Y, Yoshioka E, Yamamoto A, Kanematsu D, Handa Y, Fukusumi H, Inazawa Y, Takada AI, Nonaka M, Nakajima S, Mori K, Goto S, Kamigaki T, Shofuda T, Moriuchi S, Yamasaki M.
Anticancer Res. 2017 Jul;37(7):3921-3932. doi: 10.21873/anticanres.11775. PMID: 28668896

20.Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research.
Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, Okada N.
Mol Ther Oncolytics. 2016 Nov 16;3:16024. doi: 10.1038/mto. 2016.24. eCollection 2016. PMID: 27909701 Free PMC article.

21.Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
Yoshida Y, Naito M, Yamada T, Aisu N, Daibo K, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Yamashita Y, Hasegawa S.
Anticancer Res. 2016 Jul;36(7):3741-6. PMID: 27354648

22.Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells.
Naitoh K, Kamigaki T, Matsuda E, Ibe H, Okada S, Oguma E, Kinoshita Y, Takimoto R, Makita K, Ogasawara S, Goto S.
Anticancer Res. 2016 Jul;36(7):3715-24. PMID: 27354645

23.Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
Yamashita K, Hasegawa H, Fujita M, Nishi M, Tanaka T, Arimoto A, Suzuki S, Kamigaki T, Kakeji Y.
Anticancer Res. 2016 Jul;36(7):3659-65. PMID: 27354637

24.Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Miyashita T, Miki K, Kamigaki T, Makino I, Nakagawara H, Tajima H, Takamura H, Kitagawa H, Fushida S, Ahmed AK, Duncan MD, Harmon JW, Ohta T.
Clin Exp Med. 2017 Feb;17(1):19-31. doi: 10.1007/s10238-015-0394-x. Epub 2015 Oct 8. PMID: 26449615

Ⅱ和文原著

Ⅲ　英文総説
1.Zoledronate-pulsed dendritic cell-based anticancer vaccines: Kamigaki T, Takahara M, Maekawa R, Goto S. Oncoimmunology 2: e25636, 2013, IF:

Ⅳ　和文総説
1. がん免疫療法の分類と作用機序　免疫細胞療法とは何か
後藤重則, 神垣隆, 瀧澤憲
臨床婦人科産科 72巻6号 Page550-556(2018.06)
DOI：10.11477/mf.1409209418

2. 【悪性腫瘍と免疫療法-呼吸器悪性腫瘍を中心に-】免疫細胞療法の現状と展望
後藤重則, 瀧本理修, 牧田香理, 内藤恵子, 神垣隆
呼吸器内科 31巻4号 Page323-330(2017.04)

3. 【Precision Medicine時代の治療と診断】免疫細胞療法の現状と今後の展開
神垣隆, 阿曽沼元博, 後藤重則
映像情報Medical(1346-1354)49巻4号 Page28-33(2017.04)

4. がん免疫細胞療法　腫瘍ライセートを用いた固形腫瘍に対する樹状細胞ワクチン療法
神垣隆, 高原将司, 照屋剛, 城間寛, 善本隆之, 後藤重則
日本臨床 75巻2号 Page288-294(2017.02)

5.がん免疫治療
神垣隆, 内藤恵子, 牧田香理, 瀧本理修, 後藤重則
Source：腎臓内科・泌尿器科 3巻3号 Page294-302(2016.03)

6. 免疫細胞療法と肺がん
後藤重則), 内藤恵子, 神垣隆
呼吸器内科 28巻6号 Page463-468(2015.12)

Ⅴ　英文著書

Ⅵ　和文著書
1.T細胞輸注療法　～肺癌・膵癌を中心として～
神垣隆, 後藤重則
第8章　第3節、2016年

Ⅶ　英文報告その他
1.Saito M, Yano K, Kamigaki T, Goto S. A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). Anticancer Res 33: 2957-63, 2013, IF:

Ⅷ　和文報告その他

（科学研究費補助金・各種助成金等）
1.末梢血PD-1陽性腫瘍特異的Tリンパ球を用いた複合がん免疫療法の開発
研究種目　基盤研究(C)　
研究機関　順天堂大学
研究代表者　神垣　隆順天堂大学, 医学(系)研究科(研究院)
研究期間　　2019-04-01 – 2022-03-31

2.同種異系反応に伴う免疫活性化機構の解明と新規標的分子の同定（分担）
研究種目　基盤研究(C)　
研究機関　神戸大学
研究代表者　山下公大神戸大学, 医学部附属病院
研究期間　　2016-04-01 – 2019-03-31

3.進行食道癌におけるペプチドプールを用いた術後補助免疫療法の確立（分担）
研究種目　基盤研究(C)　
研究機関　神戸大学
研究代表者　中村哲神戸大学, 医学部附属病院
研究期間　　2015-04-01 – 2018-03-31

4.NKT細胞の自然免疫と獲得免疫のクロストークを用いた癌治療法の開発（分担）
研究種目　基盤研究(C)　
研究機関　神戸大学
研究代表者　山下公大神戸大学, 医学部附属病院
研究期間　　2013-04-01 – 2016-03-31

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

神垣 隆（カミガキ タカシ）

神垣隆（カミガキタカシ）